Holen Sie sich die Stockscreener-App
36.00
0.22%
0.08
Handel nachbörslich:
36.20
0.20
+0.56%
Schlusskurs vom Vortag:
$35.92
Offen:
$35.96
24-Stunden-Volumen:
2.40M
Relative Volume:
0.67
Marktkapitalisierung:
$15.56B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
15.65
EPS:
2.3
Netto-Cashflow:
$827.02M
1W Leistung:
+0.39%
1M Leistung:
+1.15%
6M Leistung:
+10.46%
1J Leistung:
+30.96%
1-Tages-Spanne:
$35.79
$36.22
1-Wochen-Bereich:
$35.79
$36.85
52-Wochen-Spanne:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.00 | 15.71B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Fox Run Management L.L.C. Cuts Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Syndax, Royalty Pharma enter into $350M royalty funding deal - MSN
OneAscent Investment Solutions LLC Makes New $352,000 Investment in Royalty Pharma PLC $RPRX - MarketBeat
Gulf International Bank UK Ltd Has $699,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Russell Investments Group Ltd. Sells 262,034 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Q2 Receipts Up 20% - AOL.com
Royalty Pharma plc Price Targets Raised After Rebound2025 Risk Factors & High Return Stock Watch Alerts - newsimpact.co.kr
Citigroup Inc. Has $10.39 Million Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Charles Schwab Investment Management Inc. Sells 9,097 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Virtu Financial LLC Increases Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stock Position Reduced by Deutsche Bank AG - MarketBeat
Wealthedge Investment Advisors LLC Takes Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Brandywine Global Investment Management LLC Decreases Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
22,092 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Cookson Peirce & Co. Inc. - MarketBeat
Swiss National Bank Has $33.16 Million Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stake Reduced by Forsta AP Fonden - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Buys 55,400 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Vanguard Group Inc. Has $1.14 Billion Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc Approaches Psychological Resistance LevelPortfolio Risk Report & Accurate Intraday Trade Tips - classian.co.kr
Is Royalty Pharma plc vulnerable to short sellersWeekly Investment Report & Weekly Top Stock Performers List - classian.co.kr
Earnings Chart Overlay Points to Royalty Pharma plc UpsideJuly 2025 Technicals & High Yield Stock Recommendations - beatles.ru
Can Royalty Pharma plc expand its profit margins2025 Risk Factors & Daily Risk Controlled Trade Plans - thegnnews.com
Koss Olinger Consulting LLC Has $989,000 Stock Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Henry Fernandez Steps Down from Royalty Pharma’s Board of Directors - citybiz
Royalty Pharma lead independent director Fernandez steps down By Investing.com - Investing.com Canada
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - The Manila Times
Cary Street Partners Financial LLC Buys Shares of 19,580 Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Henry Fernandez steps down from Royalty Pharma board - StreetInsider
Royalty Pharma's Lead Independent Director Exits Following Successful Post-IPO Growth Period - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Raised to Buy at Wall Street Zen - MarketBeat
Ex-Dividend Reminder: Eli Lilly, Teleflex and Royalty Pharma - Nasdaq
5 Insightful Analyst Questions From Royalty Pharma’s Q2 Earnings Call - Yahoo Finance
Is Royalty Pharma plc a potential multi baggerGlobal Markets & Fast Gaining Stock Reports - kangso.co.kr
Morgan Stanley Maintains a Buy Rating on Royalty Pharma Plc (RPRX) With a $55 PT - Insider Monkey
RPRX Q2 Deep Dive: Margins Compress Despite Solid Royalty Growth and Strategic Investments - Yahoo Finance
Royalty Pharma Director Norden Gregory Sells 33,500 Shares at $36.23 on 8/11/2025 - AInvest
CenterBook Partners LP Sells 41,728 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model - MSN
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
3.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):